Frontiers in Psychiatry
July 20, 2026
Sergio Pérez Rosal, Sonya C. Faber, Markus Backmund
Substance use disorders (SUD) involving ketamine, cocaine, and alcohol present significant clinical challenges, often characterized by high relapse rates and limited pharmacological options. This case report details a 30-year-old male with a five-year history of severe polysubstance dependence, including daily intranasal ketamine use (2–3 g/day), cocaine, and alcohol, comorbid with recurrent...
Psychedelics
July 18, 2026
Sergio Pérez Rosal, Sonya C. Faber
Background In natural product psilocybin retreats, "dose" is commonly defined by grams of dried mushrooms, despite substantial batch-to-batch variability in psilocybin content. This limits safety predictability and undermines reproducibility and between-study comparability. We report an observational field evaluation of an existing, ICH Q2(R1)-validated rapid colorimetric/photometric assay...
Scientific Reports
July 11, 2026
Monnica T. Williams, Sonya C. Faber, Jordan Sloshower et al.
This preliminary study explored the effects of MDMA-assisted therapy on trauma symptoms related to discrimination, as measured by the Trauma Symptoms of Discrimination Scale (TSDS). A total of five diverse participants, who experienced multiple types of discrimination (e.g., gender, racial/ethnic, social class, age, sexual orientation), were assessed before and after treatment. A paired-samples...
Psychedelics
July 1, 2026
Sergio Pérez Rosal, Sonya C. Faber, M. Myriah MacIntyre et al.
Background Racism and discrimination are pervasive social determinants of health, yet mainstream mental health care often fails to address the psychological sequelae of racial trauma, or race-based traumatic stress (RBTS). While psychedelic-assisted therapy (PAT) has re-entered the scientific mainstream, empirical guidance for culturally attuned, integrative care is limited. This study explores...
Research Square
November 17, 2025
Sergio Pérez Rosal, Sonya C. Faber
Abstract Natural variation in psilocybin content across mushroom samples presents a significant challenge to consistent dosing in both research and retreat settings. In this observational report, we describe a pragmatic approach for quantifying psilocybin content in naturally sourced material to ensure more standardized dosing across participants. Eleven individuals participated in a 7-day...
Journal of Contextual Behavioral Science
July 1, 2025
Oscar Soto-Angona, Amanda Rodríguez‐Urrutia, Josep Antoni Ramos‐quiroga et al.
1 citation
Altres ajuts: acords transformatius de la UAB
Commun Psychol
April 13, 2025
Martha N. Havenith, Max Leidenberger, Jelena Brasanac et al.
14 citations
Abstract Altered states of consciousness (ASCs), induced e.g. during psychedelic-assisted therapy, show potential to treat prevalent mental health disorders like depression and posttraumatic stress disorder. However, access to such treatments is restricted by legal, medical, and financial barriers. Circular breathwork may present a non-pharmacological and hence more accessible alternative to...
BMC Medical Education
October 24, 2024
Susanne Birnkammer, Olga Chernoloz, Sergio Pérez Rosal et al.
10 citations
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psychedelic-assisted therapy (PAT) and supporting psychedelic drug research. This paper evaluates the necessary frameworks for implementing PAT in Germany, emphasizing the nation's potential leadership role within the European Union. With Australia having...
Research Square
February 22, 2024
Martha N. Havenith, Max Leidenberger, Jelena Brasanac et al.
3 citations
Abstract Altered states of consciousness (ASCs), induced e.g. by psychedelics, show great potential to treat widespread mental health disorders like depression and PTSD. However, access to such treatments is restricted by legal, medical, and financial barriers. Here, we explore the potential of circular breathwork to serve as an accessible, non-pharmacological alternative to engage similar...
Fortschritte der Neurologie · Psychiatrie
January 4, 2023
Uwe Herwig, Lea J. Mertens, Sergio Pérez Rosal et al.
6 citations
Zusammenfassung In den letzten Jahren erlebte die klinische Forschung zur therapeutischen Wirksamkeit von Psychedelika eine Art Renaissance. Der aktuelle Stand wissenschaftlicher Erkenntnisse zur Wirksamkeit bei verschiedenen psychiatrischen Indikationen, wie auch die bereits unter bestimmten Voraussetzungen genehmigungsfähige Anwendung einiger psychedelischer Substanzen in der klinischen...